From accelerating the global expansion of domestically developed drugs to speeding up the introduction of major international products, Shanghai's Pudong New Area is playing an increasingly important role in connecting China's pharmaceutical innovation with the global market.

Hua Medicine, an innovative drug development and commercialization company based in Pudong, recently announced that Dorzagliatin, the world's first-in-class glucokinase activator for the treatment of type 2 diabetes in adults, has received approval from the Drug Office of the Department of Health in Hong Kong. The milestone marks a pivotal step in the company's strategic expansion from China into Southeast Asian and global markets.

Staff members are conducting research in the laboratory. [Photo/WeChat ID: pdnews]

Hansoh Pharmaceutical Group, headquartered in Pudong, announced the commercial launch of Aumolertinib Mesylate Tablets as a monotherapy in the European Union (EU). The therapy is indicated for the first-line treatment of adult patients with advanced Non-Small Cell Lung Cancer.

As the first China-originated epidermal growth factor receptor tyrosine kinase inhibitor approved in the EU, the medicine marks a breakthrough for Chinese-developed targeted therapies for lung cancer in the European market.

Boehringer Ingelheim, a multinational pharmaceutical company in Pudong, announced that its nerandomilast tablets have been prescribed for the first time in Shanghai for the treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.

Pulmonary fibrosis is a progressive, often irreversible, and fatal lung disease. Nerandomilast represents a milestone in the treatment of this condition. The drug can significantly slow the decline of lung function while demonstrating favorable safety and tolerability, addressing a key unmet clinical need for patients who discontinue treatment due to poor tolerability.